Hematology/Oncology

• Cover Stories

• SERMs: Underused and under the radar

• HemOnc Today, October 10, 2010
• The selective estrogen receptor modulators tamoxifen and raloxifene have been shown to reduce the risk for breast cancer in women at high risk by as much...More »

• In the Journals

• Surgery lowered risk for breast, ovarian cancer in women with BRCA1 and BRCA2 mutations

• September 2, 2010
• Surgery — either mastectomy or salpingo-oophorectomy — reduced the risk for breast or ovarian cancer in women who were positive for BRCA1 and BRCA2...More »

• In the Journals

• Decreases in adolescent tobacco use leveling off

• August 31, 2010
• Declines in rates of adolescent tobacco use have stagnated in the past few years, prompting the CDC to call for better prevention efforts, according to a...More »

• HPV vaccine: Used widely in United States, not always strongly recommended

• August 2, 2010
• Within 18 months of licensure, administration of the human papillomavirus vaccine began in nearly all family physician and pediatrician offices in the...More »

• ACIP updates recommendations for HPV vaccines

• May 28, 2010
• The CDC now recommends routine and catch-up vaccination for girls and women aged 11 to 26 years with either the bivalent or quadrivalent human...More »

• In the Journals

• Tanning bed use associated with 74% increased risk for melanoma

• May 27, 2010
• Results of a study published online Thursday showed that those who use tanning beds are at high risk for developing melanoma and the risk increases in...More »

• Cancer prevention focused diet

• April 28, 2010
• In a continuing effort to "walk the walk" that I ask my patients to walk when I counsel them on lifestyle changes, I have been trying to adhere more...More »

• Statins had no chemoprotective effect on colorectal cancer risk

• April 22, 2010
• AACR 101st Annual Meeting
  Statins did not protect against colorectal adenomas, and in patients at high risk for developing these lesions, they may have...More »

• STAR P-2: Raloxifene as effective as tamoxifin, but with fewer side effects

• April 19, 2010
• AACR 101st Annual Meeting
  WASHINGTON, D.C. — Updated results of the Study of Tamoxifen and Raloxifene P-2 indicated that at 81 months follow-up, the...More »

• Primary, secondary prevention fronts for breast cancer

• March 12, 2010
• Great news on the primary and secondary prevention fronts for breast cancer, recently. From the 2010 San Antonio Breast Cancer Symposium, oral...More »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!